Clinical Outcomes in Hospitalized Patients with Cancer and New versus Preexistent Atrial Fibrillation

Area of Science:

• Cardiology
• Oncology
• Clinical Research

Background:

• Limited data exists on the prognostic implications of new onset atrial fibrillation (AF) versus preexistent AF in hospitalized cancer patients.
• Atrial fibrillation is a common arrhythmia with significant cardiovascular implications.

Purpose of the Study:

• To compare the clinical impact of new onset AF (NOAF) versus preexistent AF in hospitalized cancer patients.
• To evaluate the association of NOAF with adverse clinical outcomes, including mortality, cardiovascular rehospitalization, and cerebrovascular events.

Main Methods:

• A registry of hospitalized cancer patients with AF was established over one year.
• Proportional hazards regression was used to analyze the relationship between NOAF and composite outcomes, accounting for the competing risk of death.
• Data from 606 patients were analyzed, with 313 experiencing NOAF and 293 having preexistent AF.

Main Results:

• Patients with NOAF were younger and had fewer prior cardiovascular disease (CVD) histories compared to those with preexistent AF.
• NOAF was associated with a significantly higher adjusted hazard for the primary composite outcome (all-cause death, CV rehospitalization, or cerebrovascular event) (HR 1.64, P=0.002).
• A higher risk was also observed for a secondary composite outcome including AF recurrence, CV death, CV rehospitalization, or CVE (HR 2.17, P<0.0001).

Conclusions:

• New onset AF in hospitalized cancer patients portends a worse prognosis compared to preexistent AF.
• NOAF is independently associated with an increased risk of major adverse cardiovascular events and death in this population.
• Further research is warranted to explore mechanisms and optimize management strategies for NOAF in cancer patients.